title: Nucleoside and nucleotide modulation of genetic expression--a new approach to chemotherapy.
abstract: Unlike conventional enzymes, receptors that activate G proteins do not catalyze the direct formation or cleavage of covalent bonds but act instead as a catalyst for the exchange of GTP vs GDP, which results in major conformational changes in the alpha subunit of G proteins and dissociation and selective binding of the alpha subunit which provokes direct enzyme activation eventually resulting in stimulation of protein kinase A, B or C. Each of these kinases can phosphorylate specific DNA binding proteins which allow new portions of DNA to be read and expressed. Such a series of events can act as switches to control cellular genetic expression resulting in cellular proliferation, differentiation or hormonal secretion of growth factors (Scheme I). Examples of nucleosides and nucleotides which appear to exert their therapeutic effects via G protein control of cellular proliferation resulting in differentiation are tiazofurin, selenazofurin, and 8-chloro-cAMP which have been synthesized and studied in our laboratories. The clinical application of these nucleosides in cancer treatment is presently underway and offers a viable alternative to chemotherapy with highly cytotoxic agents. The use of these derivatives result in down-regulation of the G protein regulatory pathways responsible for rapid cell division. Alternatively, a series of guanosine analogs prepared in our laboratories, 8-bromoguanosine, 8-mercaptoguanosine, 7-methyl-8-oxoguanosine and 7-thia-8-oxoguanosine, all activate various aspects of the immune response by up-regulation of G protein regulatory pathways in various lymphocyte derived cells. Guanosine-like nucleosides which function in this manner could have major clinical application as antitumor, antiviral and antimetastatic agents providing the desired specificity can be achieved. Specific immune enhancement of the aged might be an attainable goal if suitable orally active guanosine derivatives with high specificity can be achieved. The G protein regulatory pathways for modulation of genetic expression in specific cell types provide a major modern approach to new chemotherapeutic agents.
authors.affiliation: ICN Nucleic Acid Research Institute, Costa Mesa, California 92626.
authors.forename: R K
authors.initials: RK
authors.lastname: Robins
authors.forename: E
authors.initials: E
authors.lastname: Ojo-Amaize
authors.forename: Z
authors.initials: Z
authors.lastname: Parandoosh
authors.forename: H B
authors.initials: HB
authors.lastname: Cottam
authors.forename: S S
authors.initials: SS
authors.lastname: Matsumoto
authors.forename: G R
authors.initials: GR
authors.lastname: Revankar
authors.forename: D F
authors.initials: DF
authors.lastname: Smee
authors.forename: J M
authors.initials: JM
authors.lastname: Fujitaki
authors.forename: R C
authors.initials: RC
authors.lastname: Willis
authors.forename: B
authors.initials: B
authors.lastname: Rubalcava
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects; D019204:GTP-Binding Proteins / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D009705:Nucleosides / Q000494:pharmacology*; D009711:Nucleotides / Q000494:pharmacology*; D016566:Organoselenium Compounds; D010766:Phosphorylation; D012254:Ribavirin / Q000031:analogs & derivatives / Q000494:pharmacology; D012263:Ribonucleosides / Q000494:pharmacology; D012643:Selenium / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D009705:Nucleosides; D009711:Nucleotides; D016566:Organoselenium Compounds; D012263:Ribonucleosides; D012254:Ribavirin; D019204:GTP-Binding Proteins; D012643:Selenium; C039064:selenazofurin; C033706:tiazofurin